Multispecific antigen-binding molecules and uses thereof

Multispecific antigen-binding molecules link target molecules with internalizing effector proteins for enhanced degradation, addressing the complexity and side effects of traditional strategies by effectively attenuating target molecule activity.

JP7579291B2Active Publication Date: 2024-11-07REGENERON PHARMACEUTICALS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022008369
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2013-01-11
Filing Date
2022-01-24
Publication Date
2024-11-07
Estimated Expiration
2033-03-13

AI Technical Summary

Technical Problem

Existing therapeutic strategies for inactivating or attenuating target molecules often involve substantial technical complexity and side effects, necessitating alternative non-blocking methods to reduce target molecule concentration or activity.

Method used

Development of multispecific antigen-binding molecules that simultaneously bind to a target molecule and an internalizing effector protein, promoting physical linkage and internalization for degradation, thereby attenuating the target molecule's activity without blocking its interaction.

Benefits of technology

The multispecific antigen-binding molecules effectively attenuate target molecule activity by enhancing internalization and degradation, offering a more efficient and potentially less side-effect prone approach compared to traditional methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579291000001
    Figure 0007579291000001
  • Figure 0007579291000002
    Figure 0007579291000002
  • Figure 0007579291000003
    Figure 0007579291000003
Patent Text Reader

Abstract

Multispecific antigen-binding molecules and uses thereof are provided. [Solution] The multispecific antigen-binding molecules of the present invention comprise a first antigen-binding domain that specifically binds to a target molecule and a second antigen-binding domain that specifically binds to an internalizing effector protein, and in some embodiments, can be bispecific antibodies capable of binding to both the target molecule and the internalizing effector protein. In some embodiments, simultaneous binding to the target molecule and the internalizing effector protein attenuates the activity of the target molecule to a greater extent than binding of the target molecule alone. In other embodiments, the target molecule is a tumor-associated antigen, and simultaneous binding to the tumor-associated antigen and the internalizing effector protein causes or promotes targeted killing of tumor cells.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to the field of therapeutic proteins, in particular those capable of inactivating, blocking, attenuating, excreting and / or reducing the concentration of one or more target molecules in vitro or in vivo. [Background technology]

[0002] background Therapeutic treatments often require the inactivation or blocking of one or more target molecules acting on or near a cell. For example, antibody-based therapies often work by binding to a particular antigen or soluble ligand expressed on the cell surface, thereby interfering with the antigen's normal biological activity. Antibodies and other binding constructs against various cytokines (e.g., IL-1, IL-4, IL-6, IL-13, IL-22, IL-25, IL-33, etc.) or their respective receptors, as examples, have been shown to be useful for treating a wide variety of human illnesses and diseases. This type of therapeutic typically works by blocking the interaction of the cytokine with its receptor to attenuate or inhibit cell signaling. However, in some contexts, it would be therapeutically effective to inactivate or inhibit the activity of a target molecule in a manner that does not necessarily involve blocking its physical interaction with another component. One way to attenuate a target molecule without such blocking would be to reduce its extracellular or cell surface concentration. Although gene and nucleic acid-based strategies for reducing the amount or concentration of a given target molecule are known in the art, such strategies often involve substantial technical complexity and unintended side effects in therapeutic situations.Therefore, alternative non-blocking strategies are needed to facilitate the inactivation or attenuation of various target molecules for therapeutic purposes. Summary of the Invention

[0003] BRIEF SUMMARY OF THE INVETION The present invention is based, at least in part, on the idea of ​​attenuating or inactivating a target molecule by promoting or creating a physical link between the target molecule and an internalizing effector protein. Through this type of physical intermolecular link, the target molecule can be forced to be internalized into the cell together with the internalizing effector protein and processed by the intracellular degradation machinery, or can be otherwise attenuated, separated, or inactivated. This mechanism represents a novel and inventive strategy for inactivating or attenuating the activity of a target molecule without necessarily blocking the interaction between the target molecule and its binding partner.

[0004] Thus, the present invention provides a multispecific antigen-binding molecule capable of simultaneously binding to a target molecule (T) and an internalizing effector protein (E). More specifically, the present invention provides a multispecific antigen-binding molecule comprising a first antigen-binding domain (D1) and a second antigen-binding domain (D2), in which D1 specifically binds to T and D2 specifically binds to E, and the multispecific antigen-binding molecule simultaneously binds to T and E, thereby attenuating the activity of T to a greater extent than if only D1 binds to T. Further attenuation of the activity of T may be due to forced internalization / degradation of T through its physical linkage to E; however, other mechanisms of action are possible and are not excluded from the scope of the present invention.

[0005] In addition, the present invention provides a method of using a multispecific antigen-binding molecule to inactivate or attenuate the activity of a target molecule (T). In particular, the present invention provides a method of inactivating or attenuating the activity of T by contacting T and an internalizing effector protein (E) with a multispecific antigen-binding molecule, wherein the multispecific antigen-binding molecule comprises a first antigen-binding domain (D1) and a second antigen-binding domain (D2), D1 specifically binds to T, D2 specifically binds to E, and the multispecific antigen-binding molecule simultaneously binds to T and E, thereby attenuating the activity of T to a greater extent than when only D1 binds to T.

[0006] In certain embodiments of the present invention, D1 and / or D2 comprise at least one antibody variable region. For example, the multispecific antigen binding molecule may in some embodiments be a bispecific antibody, in which D1 comprises an antibody heavy and light chain variable region (HCVR / LCVR) pair that specifically binds to T, and D2 comprises an HCVR / LCVR pair that specifically binds to E. Alternatively, D1 and / or D2 may comprise a peptide or polypeptide that specifically interacts with a target molecule (T) and / or an internalizing effector protein (E). For example, if the target molecule is a cell surface receptor, D1 may comprise a portion of a ligand that specifically binds to a cell surface receptor target molecule. Similarly, if the internalizing effector protein is a cell surface internalizing receptor, D2 may comprise a portion of a ligand that specifically binds to a cell surface internalizing receptor. In certain embodiments, D1 comprises an antibody variable region that specifically binds to T, and D2 comprises a peptide or polypeptide that specifically binds to E. In still other embodiments, D1 comprises a peptide or polypeptide that specifically binds to T, and D2 comprises an antibody variable region that specifically binds to E. In either structure, however, the end result is that T and E can be physically linked, either directly, or indirectly through simultaneous binding of T and E by a multispecific antigen-binding molecule.

[0007] [The present invention 1001] a first antigen-binding domain (D1); and a second antigen-binding domain (D2); A multispecific antigen-binding molecule comprising: D1 specifically binds to a target molecule (T); and D2 specifically binds to the internalizing effector protein (E); A multispecific antigen-binding molecule in which simultaneous binding to T and E attenuates the activity of T to a greater extent than when only D1 binds to T. [The present invention 1002] The multispecific antigen-binding molecule of the present invention, wherein E is a cell surface expressed molecule that is directly internalized into the cell. [The present invention 1003] 1002. The multispecific antigen-binding molecule of the present invention, wherein E is selected from the group consisting of CD63, MHC-I, Kremen-1, Kremen-2, LRP5, LRP6, transferrin receptor, LDLr, MAL, V-ATPase, and ASGR. [The present invention 1004] The multispecific antigen-binding molecule of the present invention 1002, wherein D2 comprises a ligand or a portion of a ligand that specifically binds to E. [The present invention 1005] The multispecific antigen-binding molecule of the present invention, wherein E is a soluble ligand that is internalized into the cell via interaction of E with an internalizing cell surface expressed receptor molecule. [The present invention 1006] The multispecific antigen-binding molecule of the present invention 1005, wherein E is transferrin or a portion thereof capable of binding to a membrane-expressed transferrin receptor. [The present invention 1007] The multispecific antigen-binding molecule of the present invention 1005, wherein D2 comprises a receptor or a ligand-binding portion of a receptor that specifically binds to E. [The present invention 1008] The multispecific antigen-binding molecule of the present invention, wherein T is a cell surface expressed target molecule. [The present invention 1009] The multispecific antigen-binding molecule of the present invention, wherein T is selected from the group consisting of IL-4R, IL-6R, PRLR, Nav1.7, GCGR, and HLA-B27. [The present invention 1010] The multispecific antigen-binding molecule of the present invention, wherein D1 comprises a ligand or a portion of a ligand that specifically binds to T. [The present invention 1011] The multispecific antigen-binding molecule of the present invention, wherein T is a secreted protein or an intracellular precursor of a transmembrane protein. [The present invention 1012] The multispecific antigen-binding molecule of the present invention, wherein T is a soluble target molecule. [The present invention 1013] The multispecific antigen-binding molecule of the present invention, wherein T is selected from the group consisting of IL-4, IL-6, IL-13, SOST, and DKK1. [The present invention 1014] The multispecific antigen-binding molecule of the present invention, wherein D1 comprises a receptor or a ligand-binding portion of a receptor that specifically binds to T. [The present invention 1015] The multispecific antigen-binding molecule of the present invention, wherein D1 and / or D2 exhibit pH-dependent binding to the antigen. [The present invention 1016] The multispecific antigen-binding molecule of the present invention, wherein D1 binds to T with lower affinity at acidic pH compared to neutral pH; and / or D2 binds to E with lower affinity at acidic pH compared to neutral pH. [The present invention 1017] The multispecific antigen-binding molecule of the present invention, wherein D1 and / or D2 comprise at least one antibody variable region. [The present invention 1018] The multispecific antigen-binding molecule of the present invention, wherein D1 and / or D2 comprise a heavy chain variable region (HCVR) and a light chain variable region (LCVR). [The present invention 1019] The multispecific antigen-binding molecule of the present invention is a bispecific antibody. [The present invention 1020] The multispecific antigen-binding molecule of the present invention, wherein D1 is derived from an antigen-binding molecule that binds to T but does not substantially inactivate T by itself. [The present invention 1021] A method of inactivating a target molecule (T) or attenuating the activity of T, comprising contacting T and an internalizing effector protein (E) with a multispecific antigen-binding molecule, wherein the multispecific antigen-binding molecule comprises a first antigen-binding domain (D1) and a second antigen-binding domain (D2), wherein D1 specifically binds to T and D2 specifically binds to E; and simultaneous binding of the multispecific antigen-binding molecule to T and E causes inactivation of T to a greater extent than binding of D1 alone to T. [The present invention 1022] The method of any one of claims 10 to 21, wherein E is a cell surface expressed molecule that is directly internalized by the cell. [The present invention 1023] The method of any one of claims 10 to 12, wherein E is a soluble ligand that is internalized into the cell via interaction of E with an internalizing cell surface expressed receptor molecule. [The present invention 1024] The method of any one of claims 1 to 21, wherein T is a cell surface expressed target molecule. [The present invention 1025] The method of any one of claims 10 to 21, wherein T is a soluble target molecule. [The present invention 1026] 1001. A multispecific antigen-binding molecule of the present invention, wherein D2 comprises an antigen-binding portion of an anti-CD63 antibody. [The present invention 1027] The multispecific antigen-binding molecule of the present invention, wherein D1 comprises an antigen-binding portion of an anti-IL-4R antibody. [The present invention 1028] The multispecific antigen-binding molecule of the present invention, wherein D1 comprises an antigen-binding portion of an anti-SOST antibody. [The present invention 1029] a first antigen-binding domain (D1); and a second antigen-binding domain (D2); A multispecific antigen-binding molecule comprising: D1 specifically binds to a target molecule (T); and D2 binds to the internalizing effector protein (E), T is a tumor-associated antigen; and wherein simultaneous binding of the multispecific antigen-binding molecule to T and E induces internalization of the multispecific antigen-binding molecule into tumor cells. [The present invention 1030] The multispecific antigen-binding molecule of the present invention 1029, which is conjugated to a drug, a toxin, or a radioisotope. [The present invention 1031] A multispecific antigen-binding molecule of the present invention, wherein D2 binds to E with low affinity. [The present invention 1032] A method of targeting a tumor in a subject comprising administering to the subject a multispecific antigen-binding molecule of the present invention and a second antigen-binding protein that specifically binds to T at an epitope that does not overlap with the epitope bound by D1. [The present invention 1033] The method of claim 1032, wherein the second antigen binding protein is conjugated to a drug, toxin, or a radioisotope. Other aspects will become apparent from consideration of the following detailed description. [Brief description of the drawings]

[0008] [Figure 1] (Panels A-D) provide schematic diagrams of four general exemplary mechanisms of action for the multispecific binding molecules of the invention. In each illustrated structure, D1 is the first antigen-binding domain, D2 is the second antigen-binding domain, T is the targeting molecule, E is an internalizing effector protein, and R is a receptor that internalizes upon binding to E. Panel A shows the situation where both T and E are membrane-associated. Panel B shows the situation where T is soluble and E is membrane-associated. Panel C shows the situation where T is membrane-associated and E is a soluble protein that interacts with it and is internalized into the cell via the interaction of E and R. Panel D shows the situation where T is soluble and E is a soluble protein that interacts with it and is internalized into the cell via the interaction of E and R. [Diagram 2] The results of immunoprecipitation experiments performed on two different types of cells (cells-1 expressing only FcγR1, and cells-2 expressing Krm2 and FcγR1) after incubation with DKK1-mFc multispecific antigen-binding molecules for different periods of time (0, 15, 30, and 60 min) are shown. [Diagram 3] IL-4-induced relative luminescence produced by Stat6-luc reporter HEK293 cells at various concentrations of IL-4 in the presence and absence of anti-IL-4R / anti-CD63 multispecific antigen-binding protein ("antibody conjugate") or control constructs ("Control 1" and "Control 2") is shown. [Figure 4] Shown are the results of an experiment performed in the same manner as that shown in FIG. 3, except that CD63 expression was significantly reduced in the reporter cell line by siRNA against CD63. [Diagram 5]3 and 4, except that reporter cells were incubated with a multispecific antigen binding protein ("antibody conjugate") or control constructs ("Control 1" and "Control 2") for 2 hours or overnight before addition of IL-4 ligand. The top bar graph represents the results of an experiment performed in cells expressing normal levels of CD63 ("non-transfected cells"), and the bottom bar graph represents the results of an experiment performed in cells in which CD63 expression was significantly reduced in the reporter cell line by siRNA against CD63. [Figure 6] Illustrated are the results of experiments performed in a similar manner to those shown in FIGS. 3 and 4, except that reporter cells were incubated with anti-IL-4R / anti-CD63 multispecific antigen-binding protein ("antibody conjugate"), or control constructs ("Control 1" and "Control 2") for 15 minutes, 30 minutes, 1 hour, or 2 hours prior to the addition of IL-4 ligand. [Figure 7] Shown are the results of an experiment in which Stat6-luc reporter cells were treated with 10 pM IL-4 in the presence of various dilutions of anti-IL-4R x anti-CD63 bispecific antibody ("bispecific") or control constructs (anti-IL-4R monospecific, or mock bispecific that binds only to IL-4R). [Figure 8] 1 shows the results of an experiment in which HEK293 cells were treated with SOST constructs labeled with a myc tag and a pH-sensitive label (which produces a fluorescent signal at low pH) along with various monospecific and bispecific antibodies as indicated. Results are expressed in terms of the number of fluorescent spots (i.e., labeled vesicles) per cell. Panel A shows the results after 3 hours of incubation in ice, Panel B shows the results after 1 hour of incubation at 37° C., and Panel C shows the results after 3 hours of incubation at 37° C. [Figure 9]Shown are the results of experiments in which non-internalized (i.e., surface-bound) fluorophores were quenched after treatment of HEK293 cells with fluorescently labeled lipopolysaccharide (LPS) from E. coli (panel A) or S. minnesota (panel B) for various times with anti-CD63 x anti-LPS bispecific antibody, control antibody, or LPS alone. The fluorescent signal therefore reflects internalized LPS at the various conditions shown. Results are expressed in terms of the number of fluorescent spots (i.e., labeled vesicles) per cell. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Detailed Description Before describing the present invention, it is to be understood that the present invention is not limited to the particular methods and experimental conditions described, as such methods and conditions may vary. Similarly, it is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, as the scope of the present invention will be limited only by the appended claims.

[0010] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs.The term "about" used herein, when used with reference to a specific cited value, means that the value may vary from the cited value by 1% or less.For example, the expression "about 100" used herein includes 99 and 101 and all values ​​therebetween (for example, 99.1, 99.2, 99.3, 99.4, etc.).

[0011] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.

[0012] Multispecific antigen binding molecules The present inventors have surprisingly discovered that the activity of a target molecule can be attenuated by linking the target molecule to an internalizing effector protein via a multispecific antigen-binding molecule.

[0013] Thus, the present invention provides a multispecific antigen-binding molecule comprising a first antigen-binding domain (also referred to herein as "D1") and a second antigen-binding domain (also referred to herein as "D2"). D1 and D2 each bind to a different molecule. D1 specifically binds to a "target molecule". The target molecule is also referred to herein as "T". D2 specifically binds to an "internalizing effector protein". The internalizing effector protein is also referred to herein as "E". In accordance with the present invention, simultaneous binding of the multispecific antigen-binding molecule to T and E attenuates the activity of T to a greater extent than when only D1 binds to T. In the context of a multispecific antigen-binding molecule, the phrase "simultaneously binds" as used herein means that the multispecific antigen-binding molecule can contact both the target molecule (T) and the internalizing effector protein (E) for at least some period of time under physiologically relevant conditions to promote physical association of T and E. The binding of the multispecific antigen-binding molecule to the T and E components can be sequential; for example, the multispecific antigen-binding molecule can first bind to T and then to E, or first bind to E and then to T. In any case, as long as both T and E are bound to the multispecific antigen-binding molecule for any period of time (regardless of the order of binding), the multispecific antigen-binding molecule is considered to be "concurrently bound" to T and E for the purposes of this disclosure. Without wishing to be bound by theory, the enhanced inactivation of T appears to be caused by the re-direction of the internalization and degradation pathway of T within the cell due to its physical association with E. The multispecific antigen-binding molecules of the present invention are thus useful for inactivating and / or reducing the activity and / or extracellular concentration of a target molecule without directly blocking or antagonizing the function of the target molecule.

[0014] According to the present invention, a multispecific antigen-binding molecule can be one multifunctional polypeptide or a multimeric complex of two or more polypeptides covalently or non-covalently associated with each other. As will be evident from the present disclosure, any antigen-binding construct that has the ability to simultaneously bind to T and E molecules is considered a multispecific antigen-binding molecule. Any of the multispecific antigen-binding molecules of the present invention or variants thereof can be constructed using standard molecular biology techniques (e.g., recombinant DNA and protein expression techniques), as known to those skilled in the art.

[0015] Antigen-binding domain The multispecific antigen-binding molecule of the present invention comprises at least two distinct antigen-binding domains (D1 and D2). As used herein, the term "antigen-binding domain" refers to any peptide, polypeptide, nucleic acid molecule, scaffold molecule, peptide display molecule, or polypeptide-containing construct that can specifically bind to a particular antigen of interest. As used herein, "specifically binds" or other terms refer to an antigen-binding domain that specifically binds to a specific antigen of interest with a dissociation constant (K D ) and does not bind to other unrelated antigens under normal test conditions. An "unrelated antigen" is a protein, peptide, or polypeptide that has less than 95% amino acid identity with another antigen.

[0016] Exemplary categories of antigen-binding domains that can be used in the context of the present invention include antibodies, antigen-binding portions of antibodies, peptides that specifically interact with a particular antigen (e.g., peptibodies), receptor molecules that specifically interact with a particular antigen, proteins comprising the ligand-binding portion of a receptor that specifically binds to a particular antigen, antigen-binding scaffolds (e.g., DARPins, HEAT repeat proteins, ARM repeat proteins, tetratricopeptide repeat proteins, and other scaffolds based on naturally occurring repeat proteins, etc. [see, e.g., Boersma and Pluckthun, 2011, Curr. Opin. Biotechnol. 22:849-857, and references cited therein]), and aptamers or portions thereof.

[0017] In embodiments where the target molecule or internalizing effector protein is a receptor molecule, the "antigen-binding domain" for the purposes of the present invention may comprise or consist of a ligand or a portion of a ligand that is specific for the receptor. For example, if the target molecule (T) is IL-4R, the D1 component of the multispecific antigen-binding molecule may comprise an IL-4 ligand or a portion of an IL-4 ligand that can specifically interact with the IL-4R; or if the internalizing effector protein (E) is the transferrin receptor, the D2 component of the multispecific antigen-binding molecule may comprise transferrin or a portion of transferrin that can specifically interact with the transferrin receptor.

[0018] In embodiments where the target molecule or internalizing effector protein is a ligand (e.g., a soluble target molecule) that is specifically recognized by a particular receptor, an "antigen-binding domain" for purposes of the present invention may comprise or consist of the receptor or the ligand-binding portion of a receptor. For example, if the target molecule (T) is IL-6, the D1 component of the multispecific antigen-binding molecule may comprise the ligand-binding domain of the IL-6 receptor, or if the internalizing effector protein (E) is an indirectly internalized protein (as that term is defined elsewhere herein), the D2 component of the multispecific antigen-binding molecule may comprise the ligand-binding domain of a receptor specific for E.

[0019] Methods for determining whether two molecules specifically bind to one another are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and others. For example, an antigen-binding domain used in the context of the present invention has a K of less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, less than about 50 pM, less than about 40 pM, less than about 30 pM, less than about 20 pM, less than about 10 pM, less than about 5 pM, less than about 4 pM, less than about 2 pM, less than about 1 pM, less than about 0.5 pM, less than about 0.2 pM, less than about 0.1 pM, or less than about 0.05 pM for a particular antigen (e.g., a target molecule [T] or an internalizing effector protein [E]) or a portion thereof, as measured in a surface plasmon resonance assay. D The present invention includes a polypeptide that binds at

[0020] As used herein, the term "surface plasmon resonance" refers to an optical phenomenon that allows real-time interaction analysis by detecting changes in protein concentration within a biosensor matrix, for example using a BIAcore™ system (Biacore Life Sciences division of GE Healthcare, Piscataway, NJ).

[0021] As used herein, "K D The term "equilibrium dissociation constant" refers to the equilibrium dissociation constant of a particular protein-protein interaction (e.g., an antibody-antigen interaction). Unless otherwise indicated, the K D Values ​​are determined by surface plasmon resonance assay at 25 °C. D means the value.

[0022] Antibodies and antigen-binding fragments of antibodies As indicated above, the "antigen-binding domain" (D1 and / or D2) may comprise or consist of an antibody or an antigen-binding fragment of an antibody. As used herein, the term "antibody" refers to any antigen-binding molecule or molecular complex that comprises at least one complementarity determining region (CDR) that specifically binds to or interacts with a particular antigen (e.g., T or E). The term "antibody" includes immunoglobulin molecules that comprise four polypeptide chains, i.e., two heavy chains (H) and two light chains (L) interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM). Each heavy chain comprises a heavy chain variable region (referred to herein as HCVR or VVR). H The heavy chain constant region is made up of three domains: H 1. C H 2, and C H Each light chain comprises a light chain variable region (herein LCVR or V L The light chain constant region comprises one domain (C L 1) is included. H and V LThe regions can be further subdivided into hypervariable regions called complementarity determining regions (CDRs), which are interposed between more conserved regions called framework regions (FRs). H and V L is composed of three CDRs and four FRs arranged in the following order from amino-terminus to carboxy-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the present invention, the FRs of the antibody of the present invention (or antigen-binding portion thereof) may be identical to the human germline sequence or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on the simultaneous analysis of two or more CDRs.

[0023] The D1 and / or D2 components of the multispecific antigen-binding molecules of the invention may comprise or consist of an antigen-binding fragment of a complete antibody molecule. As used herein, the "antigen-binding portion" of an antibody, the "antigen-binding fragment" of an antibody, and other terms include any naturally occurring, enzymatically obtainable, synthetic, or genetically modified polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies may be derived from complete antibody molecules using any suitable standard technique, such as, for example, proteolytic digestion, or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable domains and, optionally, constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage-antibody libraries), or may be synthesized. The DNA may be sequenced and manipulated, for example, chemically or by using molecular biology techniques, to place one or more variable and / or constant domains in a suitable structure, or to introduce codons, create cysteine ​​residues, modify, add, or delete amino acids, etc.

[0024] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues mimicking the hypervariable regions (e.g., isolated complementarity determining regions (CDRs) such as CDR3 peptides) of an antibody or constrained FR3-CDR3-FR4 peptides. Other engineered molecules such as domain-specific antibodies, single domain antibodies, domain deleted antibodies, chimeric antibodies, CDR grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains are also encompassed by the term "antigen-binding fragment" as used herein.

[0025] Antigen-binding fragments of antibodies typically contain at least one variable domain. A variable domain can be of any size or amino acid composition and generally contains at least one CDR adjacent to or in frame with one or more framework sequences. L Domain-associated V H In an antigen-binding fragment having a domain, H and V L The domains can be positioned relative to each other in any suitable configuration. For example, the variable region can be a dimer, with the V H -V H , V H -V L , or V L -V L Alternatively, the antigen-binding fragment of the antibody may comprise a monomeric V H or V L It may include a domain.

[0026] In some embodiments, an antigen-binding fragment of an antibody may comprise at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary structures of variable and constant domains that may be found within an antigen-binding fragment of an antibody of the invention include: (i) V H -C H 1;(ii)V H -C H 2;(iii)V H -C H 3;(iv)V H -C H 1-C H 2;(v)V H -C H 1-C H 2-C H 3;(vi)V H -C H 2-C H 3;(vii)V H -C L ;(viii)V L -C H 1;(ix)V L -C H 2;(x)V L -C H 3;(xi)V L -C H 1-C H 2;(xii)V L -C H 1-C H 2-C H 3;(xiii)V L -C H 2-C H 3; and (xiv) V L -C LIn any of the configurations of the variable and constant domains, including any of the exemplary structures listed above, the variable and constant domains may be directly linked to each other or may be linked by a complete or partial hinge or linker region. The hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids by which a flexible or semi-flexible linkage is obtained between adjacent variable and / or constant domains in one polypeptide molecule. Moreover, antigen-binding fragments may be linked to each other and / or to one or more monomeric V H or V L It may comprise homodimers or heterodimers (or other multimers) of any of the above variable and constant domain structures, with the domains non-covalently associated (eg, by disulfide bonds).

[0027] The multispecific antigen-binding molecules of the present invention may comprise or consist of human antibodies and / or recombinant human antibodies or fragments thereof. The term "human antibody" as used herein includes antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies may nevertheless include amino acid residues (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutation in vivo), e.g., in the CDRs and particularly in the CDR3, that are not encoded by human germline immunoglobulin sequences. However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0028] The multispecific antigen-binding molecules of the present invention may comprise or consist of recombinant human antibodies or antigen-binding fragments thereof. As used herein, the term "recombinant human antibodies" is intended to include all human antibodies prepared, expressed, produced, or isolated by recombinant means, such as antibodies expressed using recombinant expression vectors transfected into host cells (described in more detail below), antibodies isolated from recombinant combinatorial human antibody libraries (described in more detail below), antibodies isolated from animals (e.g., mice) that are transgenic for human immunoglobulin genes (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295), or antibodies prepared, expressed, produced, or isolated by any other means involving splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or, in the case of animals transgenic for human Ig sequences, in vivo somatic mutagenesis) to thereby improve the V H and V L The amino acid sequence of the region is H and V L These are sequences that are derived from and related to sequences, but may not naturally occur within the human antibody germline repertoire in vivo.

[0029] bispecific antibody According to one embodiment, the multispecific antigen-binding molecules of the present invention are bispecific antibodies, e.g., bispecific antibodies comprising an antigen-binding arm that specifically binds to a target molecule (T) and an antigen-binding arm that specifically binds to an internalizing effector protein (E). Methods for making bispecific antibodies are known in the art and can be used to construct the multispecific antigen-binding molecules of the present invention. Exemplary bispecific formats that can be used in the context of the present invention include, for example, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, quadromas, knobs-into-holes, common light chains (e.g., common light chains with knobs-into-holes), CrossMab, CrossFab, (SEED) bodies, leucine zippers, duobodies, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab. 2 These include, but are not limited to, bispecific formats (see, e.g., Klein et al. 2012, mAbs 4:6, 1-11, and references cited therein, for a review of the aforementioned formats).

[0030] Polymerization component The multispecific antigen-binding molecules of the present invention may also, in some embodiments, comprise one or more multimerization components. The multimerization components can function to maintain the association between the antigen-binding domains (D1 and D2). As used herein, a "multimerization component" is any macromolecule, protein, polypeptide, peptide, or amino acid capable of associating with a second multimerization component of the same or similar structure or composition. For example, a multimerization component may be a multimerization component that is capable of associating with an immunoglobulin C HThe multimerization component may be a polypeptide comprising three domains. A non-limiting example of a multimerization component is the Fc portion of an immunoglobulin, such as an IgG selected from isotypes IgG1, IgG2, IgG3, and IgG4, as well as the Fc domain of any allotype within each isotype group. In some embodiments, the multimerization component is an Fc fragment or an amino acid sequence having a length of 1 to about 200 amino acids and including at least one cysteine ​​residue. In other embodiments, the multimerization component is a cysteine ​​residue or a short cysteine-containing peptide. Other multimerization domains include peptides or polypeptides that include or consist of a leucine zipper, a helix loop motif, or a coiled-coil motif.

[0031] In one embodiment, the multispecific antigen-binding molecule of the present invention comprises two multimerization domains, M1 and M2, where D1 binds to M1 and D2 binds to M2, and the association of M1 and M2 promotes the physical linkage of D1 and D2 to each other in one multispecific antigen-binding molecule. In one embodiment, M1 and M2 are identical to each other. For example, M1 can be an Fc domain having a specific amino acid sequence, and M2 is an Fc domain having the same amino acid sequence as M1. Alternatively, M1 and M2 can differ from each other at one or more amino acid positions. For example, M1 is an Fc domain having a specific amino acid sequence, and M2 is an Fc domain having the same amino acid sequence as M1. H M2 is a second IgC domain. H 3 domains, the first and second Ig C H The three domains differ from each other by at least one amino acid, and the at least one amino acid difference reduces binding of the targeting construct to Protein A compared to a reference construct having identical M1 and M2 sequences. In one embodiment, the IgC of M1 H The 3 domain binds to protein A and mediates the formation of M2 IgC H The C3 domain contains mutations that reduce or abolish Protein A binding, such as the H95R (according to the IMGT exon numbering; H435R in EU numbering) modification. H3 may further include a Y96F modification (according to IMGT; Y436F in EU). H Further modifications that may be found within 3 include: for IgG1 Fc domains, D16E, L18M, N44S, K52N, V57M, and V82I (according to IMGT; in EU, D356E, L358M, N384S, K392N, V397M, and V422I); for IgG2 Fc domains, N44S, K52N, and V82I (according to IMGT; in EU, N384S, K392N, and V422I); and for IgG4 Fc domains, Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (according to IMGT; in EU, Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I).

[0032] Internalizing effector proteins (E) In the context of the present invention, the D2 component of the multispecific antigen-binding molecule specifically binds to an internalizing effector protein ("E"). An internalizing effector protein is a protein that can be internalized into a cell or that is otherwise involved in or contributes to retrograde membrane trafficking. In some cases, an internalizing effector protein is a protein that undergoes transcytosis, i.e., the protein is internalized at one side of the cell and transported to the other side of the cell (e.g., from apical to basal). In many embodiments, the internalizing effector protein is a cell surface expressed protein or a soluble extracellular protein. However, the present invention also contemplates embodiments in which the internalizing effector protein is expressed within an intracellular compartment, such as an endosome, an endoplasmic reticulum, a Golgi apparatus, a lysosome, and the like. For example, proteins involved in retrograde membrane trafficking (e.g., the pathway from early / recycling endosomes to the trans-Golgi network) may serve as internalizing effector proteins in various embodiments of the present invention. In any case, binding of D2 to an internalizing effector protein causes the entire multispecific antigen-binding molecule and any molecules associated therewith (e.g., the target molecule to which D1 binds) to be internalized by the cell as well. As described below, internalizing effector proteins include proteins that are directly internalized by cells, as well as proteins that are indirectly internalized by cells.

[0033] Internalizing effector proteins that are directly internalized into cells include membrane-associated molecules (e.g., transmembrane proteins, GPI-attachment proteins, etc.) with at least one extracellular domain that undergo cellular internalization and are preferably processed via intracellular degradation and / or recycling pathways. Specific non-limiting examples of internalizing effector proteins that are directly internalized into cells include, for example, CD63, MHC-I (e.g., HLA-B27), Kremen-1, Kremen-2, LRP5, LRP6, LRP8, transferrin receptor, LDL-receptor, LDL-related protein 1 receptor, ASGR1, ASGR2, amyloid precursor protein-like protein-2 (APLP2), apelin receptor (APLNR), MAL (myelin-lymphocyte protein, commonly known as VIP17), IGF2R, vacuolar type H + These include ATPase, diphtheria toxin receptor, folate receptor, glutamate receptor, glutathione receptor, leptin receptor, scavenger receptor (eg, SCARA1-5, SCARB1-3, CD36), and the like.

[0034] In embodiments where E is an effector protein that is directly internalized, the D2 component of the multispecific antigen-binding molecule can be, for example, an antibody or antigen-binding fragment of an antibody that specifically binds to E, or a ligand or portion of a ligand that specifically interacts with the effector protein. For example, when E is Kremen-1 or Kremen-2, the D2 component can comprise or consist of a Kremen ligand (e.g., DKK1) or a Kremen-binding portion thereof. As another example, when E is a receptor molecule such as ASGR1, the D2 component can comprise or consist of a ligand specific for the receptor or its receptor-binding portion (e.g., asialoorosomucoid [ASOR] or β-GalNAc).

[0035] Internalizing effector proteins that are indirectly internalized by cells include proteins and polypeptides that do not internalize by themselves, but become internalized by cells after binding or otherwise associating with a second protein or polypeptide that is directly internalized by cells. Proteins that are indirectly internalized by cells include, for example, soluble ligands that can bind to internalizing cell surface expressed receptor molecules. A non-limiting example of a soluble ligand that is (indirectly) internalized by cells through its interaction with an internalizing cell surface expressed receptor molecule is transferrin. In an embodiment where E is transferrin (or another indirectly internalized protein), when D2 binds to E and E interacts with the transferrin receptor (or another internalizing cell surface expressed receptor molecule), the entire multispecific antigen binding molecule and any molecules associated therewith (for example, the target molecule that D1 binds to) become internalized by the cell simultaneously with the internalization of E and its binding partner.

[0036] In embodiments where E is an indirectly internalized effector protein, such as a soluble ligand, the D2 component of the multispecific antigen binding molecule can be, for example, an antibody or antigen-binding fragment of an antibody that specifically binds to E, or a receptor or portion of a receptor that specifically interacts with the soluble effector protein. For example, where E is a cytokine, the D2 component can comprise or consist of the corresponding cytokine receptor or a ligand-binding portion thereof.

[0037] Target molecule (T) In the context of the present invention, the D1 component of the multispecific antigen-binding molecule specifically binds to a target molecule ("T"). A target molecule is any protein, polypeptide, or other macromolecule whose activity or extracellular concentration is desired to be attenuated, reduced, or eliminated. In many instances, the target molecule to which D1 binds is a protein or polypeptide [i.e., a "target protein"]; however, the present invention also includes embodiments in which the target molecule to which D1 binds ("T") is a carbohydrate, glycoprotein, lipid, lipoprotein, lipopolysaccharide, or other non-protein polymer or molecule. In accordance with the present invention, T can be a cell surface-expressed target protein or a soluble target protein. Target binding by the multispecific antigen-binding molecule can occur in an extracellular or cell surface context. However, in certain embodiments, the multispecific antigen-binding molecule binds to a target molecule inside a cell, for example, within an intracellular component such as the endoplasmic reticulum, Golgi apparatus, endosome, lysosome, etc.

[0038] Examples of cell surface expressed target molecules include cell surface expressed receptors, membrane bound ligands, ion channels, and any other monomeric or multimeric polypeptide components having an extracellular portion that binds or associates with a cell membrane. Non-limiting exemplary cell surface expressed target molecules that can be targeted by the multispecific antigen binding molecules of the invention include, for example, cytokine receptors (e.g., receptors for IL-1, IL-4, IL-6, IL-13, IL-22, IL-25, IL-33, etc.), as well as other type 1 transmembrane receptors such as PRLR, G protein-coupled receptors such as GCGR, ion channels such as Nav1.7, ASIC1 or ASIC2, MHC-1 (e.g., HLA-B * 27) and other cell surface targets including non-receptor surface proteins.

[0039] In embodiments where T is a cell surface expressed target protein, the D1 component of the multispecific antigen binding molecule can be, for example, an antibody or antigen-binding fragment of an antibody that specifically binds to T, or a ligand or portion of a ligand that specifically interacts with a cell surface expressed target protein. For example, where T is IL-4R, the D1 component can comprise or consist of IL-4 or a receptor binding portion thereof.

[0040] Examples of soluble target molecules include cytokines, growth factors, and other ligands and signaling proteins. Non-limiting exemplary soluble target proteins that can be targeted by the multispecific antigen binding molecules of the present invention include, for example, IL-1, IL-4, IL-6, IL-13, IL-22, IL-25, IL-33, SOST, DKK1, etc. Soluble target molecules also include non-human target molecules, such as allergens (e.g., Fel D1, Betv1, CryJ1), pathogens (e.g., Candida albicans, S. aureus, etc.), and pathogenic molecules (e.g., lipopolysaccharide [LPS], lipoteichoic acid [LTA], protein A, toxins, etc.). In embodiments where T is a soluble target molecule, the D1 component of the multispecific antigen-binding molecule can be, for example, an antibody or antigen-binding fragment of an antibody that specifically binds to T, or a receptor or portion of a receptor that specifically interacts with the soluble target molecule. For example, where T is IL-4, the D1 component can comprise or consist of IL-4R or a ligand-binding portion thereof.

[0041] Target molecules also include tumor-associated antigens as described elsewhere herein.

[0042] pH dependent binding The present invention provides a multispecific antigen-binding molecule comprising a first antigen-binding domain (D1) and a second antigen-binding domain (D2), in which one or both of the antigen-binding domains (D1 and / or D2) bind to its antigen (T or E) in a pH-dependent manner. For example, the antigen-binding domain (D1 and / or D2) may exhibit decreased binding to its antigen at acidic pH compared to neutral pH. Alternatively, the antigen-binding domain (D1 and / or D2) may exhibit enhanced binding to its antigen at acidic pH compared to neutral pH. An antigen-binding domain with pH-dependent binding characteristics may be obtained, for example, by screening an antibody population for decreased (or enhanced) binding to a particular antigen at acidic pH compared to neutral pH. In addition, modification of the antigen-binding domain at the amino acid level may result in an antigen-binding domain with pH-dependent characteristics. For example, an antigen-binding domain with decreased antigen binding at acidic pH compared to neutral pH may be obtained by replacing one or more amino acids of the antigen-binding domain (e.g., within the CDRs) with histidine residues.

[0043] In one embodiment, the present invention provides a method for determining the K of the D1 and / or D2 components for binding to their respective antigens at neutral pH. D At least about 3, 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 times or higher K D and a multispecific antigen-binding molecule comprising a D1 and / or D2 moiety that binds to its respective antigen (T or E) at acidic pH. pH-dependent binding also refers to the t of an antigen-binding domain with respect to its antigen at acidic pH compared to neutral pH. 1 / 2 For example, the present invention relates to the t of D1 and / or D2 components with respect to binding to their respective antigens at neutral pH. 1 / 2 At least about 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 times or more shorter than 1 / 2and a multispecific antigen-binding molecule comprising a D1 and / or D2 moiety that binds to its respective antigen (T or E) at acidic pH.

[0044] Multispecific antigen-binding molecules of the invention comprising D1 and / or D2 moieties that have reduced antigen binding at acidic pH compared to neutral pH may, in some embodiments, exhibit slower clearance from the blood when administered to an animal subject compared to a comparable molecule that does not exhibit pH-dependent binding characteristics. In accordance with this aspect of the invention, multispecific antigen-binding molecules are provided that have reduced antigen binding to either T and / or E at acidic pH compared to neutral pH, which exhibit at least 2-fold slower clearance from the blood compared to a comparable antigen-binding molecule that does not have reduced antigen binding at acidic pH compared to neutral pH. Clearance rates may be expressed in terms of antibody half-life, with slower clearance correlating with longer half-life.

[0045] As used herein, the term "acidic pH" refers to a pH of 6.0 or less. The term "acidic pH" includes pH values ​​of about 6.0, 5.95, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0, or less. As used herein, the term "neutral pH" refers to a pH of about 7.0 to about 7.4. The term "neutral pH" includes pH values ​​of 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.

[0046] Attenuation of target molecule activity As noted elsewhere herein, and as evidenced by the Examples herein below, the inventors have discovered that simultaneous binding of a multispecific antigen-binding molecule to a target molecule (T) and an internalizing effector protein (E) attenuates the activity of T to a greater extent than when only the first antigen-binding domain (D1) component of the multispecific antigen-binding molecule binds to T. As used herein, the phrase "attenuates the activity of T to a greater extent than when only D1 binds to T" means that in an assay in which the activity of T can be measured using cells expressing E, the activity level of T measured in the presence of the multispecific antigen-binding molecule is at least 10% lower than the activity level of T measured in the presence of a control construct comprising only D1 (i.e., not physically linked to the second antigen-binding domain (D2)). By way of example, the activity level of T measured in the presence of the multispecific antigen-binding molecule can be about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% lower than the activity level of T measured in the presence of a control construct comprising only D1.

[0047] Non-limiting exemplary assay formats for determining whether a multispecific antigen-binding molecule attenuates the activity of a target molecule to a greater extent than if only the D1 domain binds to the target molecule are shown in Examples 1 and 2 herein below. In Example 1, by way of example, "T" is the interleukin-4 receptor (IL-4R) and "E" is CD63. The multispecific antigen-binding molecule of Example 1 is a two-antibody conjugate comprising an anti-IL-4R mAb linked to an anti-CD63 mAb via a streptavidin / biotin linker. Thus, in this exemplary construct, "D1" is the antigen-binding domain of the anti-IL-4R antibody (HCVR / LCVR pair) and "D2" is the antigen-binding domain of the anti-CD63 antibody (HCVR / LCVR pair). For the experiments in Examples 1 and 2, a cell-based assay format was used that generates a reporter signal when IL-4R activity is stimulated by the addition of exogenous IL-4 ligand. The amount of IL-4-induced reporter activity detected in the presence of the multispecific antigen-binding molecule was compared to the amount of IL-4-induced reporter activity detected in the presence of a control construct comprising an anti-IL-4R antibody linked to an irrelevant control immunoglobulin (Control 1) or mixed with but not physically linked to an anti-CD63 antibody (Control 2). The control construct thus creates a situation in which only D1 binds to T (i.e., D1 is not itself part of the multispecific antigen-binding molecule). For the purposes of this disclosure, if the degree of target molecule activity (represented by the reporter signal) observed in the presence of the multispecific antigen-binding molecule is at least 10% lower than the amount of target molecule activity observed in the presence of a control construct (e.g., Control 1 or Control 2) that comprises the D1 component but is not physically linked to the D2 component, then it is concluded that "simultaneous binding of the multispecific antigen-binding molecule to T and E attenuates the activity of T to a greater extent than when only D1 binds to T."

[0048] Binding of D1 alone to T may, in some embodiments, result in partial attenuation of T activity (as in Example 1, where treatment of reporter cells with anti-IL-4R antibody alone [i.e., Controls 1 and 2] caused a low level of attenuation of IL-4 signaling compared to untreated controls). In other embodiments, binding of D1 alone to T may not result in detectable attenuation of T activity, i.e., binding of D1 alone to T may not affect the biological activity of T. In any case, however, simultaneous binding of the multispecific antigen-binding molecule of the present invention to T and E attenuates the activity of T to a greater extent than binding of D1 alone to T.

[0049] Alternative assay formats and modifications of the assay formats exemplified herein will be apparent to those skilled in the art, given the nature of the specific target molecules and effector proteins to which any given multispecific antigen-binding molecule may be directed. Any such format can be used in the context of the present invention to determine whether simultaneous binding of a multispecific antigen-binding molecule to T and E attenuates the activity of T to a greater extent than binding of D1 alone to T.

[0050] Tumor targeting In another aspect of the present invention, the multispecific antigen binding molecule is useful for targeting tumor cells. According to this aspect of the present invention, the target molecule "T" that D1 binds is a tumor-associated antigen. In some embodiments, the tumor-associated antigen is an antigen that is not normally internalized. The internalizing effector protein "E" that D2 binds can be tumor-specific or expressed in both tumor cells and non-tumor cells of an individual. Any of the internalizing effector proteins mentioned elsewhere herein can be targeted for the anti-tumor application of the present invention.

[0051] The term "tumor-associated antigen" as used herein includes proteins or polypeptides that are selectively expressed on the surface of tumor cells. In this context, the term "selectively expressed" means that the antigen is expressed at a level at least 10% (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 150%, 200%, 400% or more) higher in tumor cells than the expression level of the antigen in non-tumor cells. In some embodiments, the target molecule is an antigen that is selectively expressed on the surface of tumor cells selected from the group consisting of renal tumor cells, colon tumor cells, breast tumor cells, ovarian tumor cells, skin tumor cells, lung tumor cells, prostate tumor cells, pancreatic tumor cells, glioblastoma cells, head and neck tumor cells, and melanoma cells. Non-limiting examples of specific tumor associated antigens include, for example, AFP, ALK, BAGE proteins, β-catenin, brc-abl, BRCA1, BORIS, CA9, carbonic anhydrase IX, caspase-8, CD40, CDK4, CEA, CTLA4, cyclin-B1, CYP1B1, EGFR, EGFRvIII, ErbB2 / Her2, ErbB3, ErbB4, ETV6-AML, EphA2, Fra-1, FOLR1, GAGE ​​proteins (e.g., GAGE-1, -2), GD2, GD3, globoH, glypican-3, GM3, gp100, Her2, HLA / B-raf, HLA / k-ras, HLA / MAGE-A3, hTERT, LMP2, MAGE proteins (e.g., MAGE-1, -2, -3, -4, -6, and -12), MART-1, mesothelin, ML-IAP, Muc1, Muc16 (CA-125), MUM1, NA17, NY-BR1, NY-BR62, NY-BR85, NY-ESO1, OX40, p15, p53, PAP, PAX3, PAX5, PCTA-1, PLAC1, PRLR, PRAME, PSMA (FOLH1), RAGE proteins, Ras, RGS5, Rho, SART-1, SART-3, Steap-1, Steap-2, survivin, TAG-72, TGF-β, TMPRSS2, Tn, TRP-1, TRP-2, tyrosinase, and uroplakin-3.

[0052] The multispecific antigen-binding molecules according to this aspect of the invention may be conjugated to drugs, toxins, radioisotopes, or other substances that are harmful to cell survival. Or the drug or toxin may be a substance that does not directly kill the cell, but makes the cell more susceptible to killing by other exogenous substances. In yet other embodiments involving tumor targeting, the multispecific antigen-binding molecules of the present invention are not themselves conjugated to drugs, toxins, or radioisotopes, but are instead administered together with a second antigen-binding molecule (herein referred to as a "concomitant molecule") specific for the target (T) that is conjugated to a drug, toxin, or radioisotope. In such embodiments, the multispecific antigen-binding molecule preferably binds to an epitope on the target molecule (T) that is different and / or does not overlap with the epitope recognized by the concomitant molecule (i.e., allowing simultaneous binding of the multispecific antigen-binding molecule and the concomitant molecule to the target).

[0053] In a related embodiment, the present invention also includes antitumor combinations and therapeutic methods comprising: (a) a toxin or drug-conjugated antigen-binding molecule that specifically binds to a tumor-associated antigen; and (b) a multispecific antigen-binding molecule that comprises (i) a first binding domain that specifically binds (e.g., with low affinity) to an internalizing effector protein, and (ii) a second binding domain that specifically binds to the toxin- or drug-conjugated antigen-binding molecule. In this embodiment, the multispecific antigen-binding molecule functions to link the toxin or drug-conjugated antigen-binding molecule to the internalizing effector protein, thereby physically linking the tumor-associated antigen to the internalizing effector protein. Internalization of the toxin-labeled antitumor-associated antigen antibody through its binding to the internalizing effector protein will result in targeted tumor cell killing.

[0054] According to certain embodiments of the tumor targeting aspect of the invention, the multispecific antigen binding molecule (or associated antibody) may be conjugated to one or more cytotoxic agents selected from the group consisting of calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cisplatin, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, larotaxel, tesetaxel, orataxel, docetaxel, dolastatin 10, auristatin E, auristatin PHE, and maytansine-based compounds (e.g., DM1, DM4, etc.). The multispecific antigen-binding molecule (or associated antibody) may also or alternatively be conjugated to a toxin such as diphtheria toxin, Pseudomonas aeruginosa exotoxin A, ricin A chain, abrin A chain, modeccin A chain, α-sarcin, Aleurites fordii protein, dianthin protein, Phytolaca americana protein, etc. ... 225 Ac, 211 At, 212 Bi, 213 Bi, 186 Rh, 188 Rh, 177 Lu, 90 Y, 131 I, 67 Cu, 125 I, 123 I, 77 Br, 153 Sm, 166 Ho, 64 Cu, 121 Pb, 224 Ra, and 223 The antibody may be conjugated to one or more radioisotopes selected from the group consisting of Ra. Thus, this aspect of the invention includes multispecific antigen-binding molecules that are antibody-drug conjugates (ADCs) or antibody-radioisotope conjugates (ARCs).

[0055] In the context of tumor cell killing applications, the D2 component may in some circumstances bind with low affinity to the internalizing effector protein "E". In this way, the multispecific antigen binding molecule selectively targets tumor cells expressing tumor-associated antigens. As used herein, "low affinity" binding means that the binding affinity of the D2 component to the internalizing effector protein (E) is at least 10% weaker (e.g., 15% weaker, 25% weaker, 50% weaker, 75% weaker, 90% weaker, etc.) than the binding affinity of the D1 component to the target molecule (T). In some embodiments, "low affinity" binding means that the D2 component has a K of greater than about 10 nM when measured in a surface plasmon resonance assay at about 25°C. D to approximately 1 μM K D This means that it interacts with the internalizing effector protein (E) at

[0056] The simultaneous binding of the multispecific antigen-binding molecule to the internalizing effector protein and the tumor-associated antigen results in the selective internalization of the multispecific antigen-binding molecule into tumor cells. For example, when the multispecific antigen-binding molecule is conjugated to a drug, toxin, or radioisotope (or when the multispecific antigen-binding molecule is administered together with a companion antibody conjugated to a drug, toxin, or radioisotope), the tumor-associated antigen is targeted and internalized into the tumor cell, resulting in highly specific tumor cell killing via its association with the multispecific antigen-binding molecule.

[0057] Pharmaceutical Compositions and Methods of Administration The present invention includes pharmaceutical compositions comprising multispecific antigen-binding molecules. The pharmaceutical compositions of the present invention may be formulated with suitable carriers, excipients, and other substances that provide improved entry, improved delivery, improved tolerability, and the like.

[0058] The present invention also includes a method of inactivating or attenuating the activity of a target molecule (T). The method of the present invention comprises contacting the target molecule with a multispecific antigen-binding molecule as described herein. In some embodiments, the method according to this aspect of the present invention comprises administering a pharmaceutical composition comprising the multispecific antigen-binding molecule to a patient in whom it is desirable and / or beneficial to inactivate, attenuate, or otherwise reduce the extracellular concentration of the target molecule.

[0059] A variety of delivery systems are known in the art and can be used to administer the pharmaceutical composition of the present invention to a patient. The administration methods that can be used in the context of the present invention include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The pharmaceutical composition of the present invention can be administered by any convenient route, such as by infusion or bolus injection, by absorption through epithelial or mucocutaneous lining cells (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other biologically active substances. Administration can be systemic or local. For example, the pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously by a standard needle and syringe. In addition, for subcutaneous delivery, the pharmaceutical composition of the present invention can be administered to a patient using a pen delivery device. EXAMPLES

[0060] The following examples are presented so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors regard as the invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weights are average molecular weights, temperatures are in degrees Celsius, and pressures are at or near atmospheric.

[0061] Example 1. Use of multispecific antigen-binding molecules to induce degradation of cell surface receptors via linkage with internalizing effector proteins As an initial proof-of-concept experiment, we generated a multispecific antigen-binding molecule that can bind (a) an internalizing effector molecule and (b) a cell surface receptor targeting molecule. In this example, the internalizing effector protein is Kremen-2 (Krm2) and the cell surface receptor targeting molecule is an Fc receptor (FcγR1 [Fcγ-R1]).

[0062] Kremen molecules (Krm1 and Krm2) are cell surface proteins known to mediate WNT signaling by directing the internalization and degradation of the WNT pathway signaling molecules LRP5 and LRP6. LRP5 / 6 internalization is mediated by the soluble interacting protein DKK1. In detail, DKK1 links Kremen to LRP5 / 6 on the cell surface, and due to this link, when Kremen is internalized, it promotes the internalization and degradation of LRP5 and LRP6 (see Li et al., PLoS One 5(6):e11014).

[0063] The present inventors attempted to exploit the Kremen-binding properties of DKK1 and the internalization properties of Kremen to induce internalization of FcγR1. To promote Kremen-mediated internalization / degradation of FcγR1, a multispecific antigen-binding molecule consisting of DKK1 fused to mouse Fc (DKK1-mFc, having the amino acid sequence of SEQ ID NO:1) was constructed. As described elsewhere herein, a multispecific antigen-binding molecule is defined as a molecule comprising a first antigen-binding domain (D1) that specifically binds to a target molecule and a second antigen-binding domain (D2) that specifically binds to an internalizing effector protein. In this proof-of-concept example, the "first antigen-binding domain" is the mFc component that specifically binds to the target molecule FcγR1, and the "second antigen-binding domain" is the DKK1 component that specifically binds to the internalizing effector protein Kremen.

[0064] Experiments were first performed to determine whether DKK1-mFc could be endocytosed into cells in a Kremen-dependent manner. For this experiment, two cell lines were used: cell-1, a HEK293 cell line engineered to express FcγR1 but not Kremen-2, and cell-2, a HEK293 cell engineered to express both FcγR1 and Kremen-2. A 1:10 dilution of DKK1-mFc conditioned medium was added to each cell line and incubated at 37° C. for 90 minutes. After 90 minutes of incubation, cells were stained with an Alexa-488-labeled anti-mouse IgG antibody to detect DKK1-mFc molecules. Using a fluorescent microscope, it was confirmed that there was virtually no DKK1-mFc inside cell-1 (which lacks Kremen), but a substantial amount of DKK1-mFc was detected inside cell-2, which expresses Kremen-2. Thus, these results indicate that the multispecific antigen-binding molecule DKK1-mFc can be internalized into cells in a Kremen-dependent manner.

[0065] Next, a time course experiment was performed to determine whether DKK1-mFc could induce FcγR1 degradation in a Kremen-dependent manner. A brief description of the experimental protocol is described below: Cell-1 (expressing only FcγR1) and Cell-2 (expressing Kremen-2 and FcγR1) were treated with 2 mg / ml NHS-sulfobiotin for 15 min on ice to label all cell surface expressed proteins. Cells were then washed, resuspended in 400 μl of medium, and divided into four 100 μl aliquots, which were treated with DKK1-mFc for various periods (0 min, 15 min, 30 min, and 60 min) at 37°C. After DKK1-mFc incubation, cells were precipitated and treated with protease inhibitors. Lysates of cells from different incubation time points were subjected to FcγR1 immunoprecipitation. For FcγR1 immunoprecipitation, mouse anti-FcγR1 antibody was added to cell lysates and incubated at 4°C for 1 h. Protein-G beads were added and the mixture was incubated at 4°C for 1 h. The beads were then washed and proteins were eluted and subjected to SDS-PAGE. Proteins were transferred to membranes and probed with HRP-labeled streptavidin to reveal the relative amount of remaining surface-exposed FcγR1 protein in each sample. The results are shown in Figure 2.

[0066] As shown in Figure 2, the amount of surface-exposed FcγR1 protein in cell-1 (expressing FcγR1 but not Kremen-2) samples remained relatively constant regardless of the duration the cells were exposed to DKK1-mFc. In contrast, the amount of surface-exposed FcγR1 protein in cell-2 (expressing both Kremen-2 and FcγR1) samples decreased substantially with increasing incubation time with DKK1-mFc. Thus, this experiment demonstrates that DKK1-mFc induces degradation of cell surface-expressed FcγR1 in a Kremen-2-dependent manner.

[0067] Taken together, the above results indicate that a multispecific antigen-binding molecule that simultaneously binds to a cell surface target molecule (FcγR1) and an internalizing effector protein (Kremen-2) can induce degradation of the target molecule in an effector protein-dependent manner.

[0068] Example 2. IL-4R activity is attenuated using a multispecific antigen-binding molecule with specificity for IL-4R and CD63 In a further set of proof-of-concept experiments, a multispecific antigen-binding molecule was constructed that can simultaneously bind to a cell surface-expressed target molecule (i.e., IL-4R) and a cell surface-expressed internalizing effector protein (i.e., CD63). The purpose of these experiments was to determine whether IL-4R activity in cells could be attenuated to a greater extent by physically linking IL-4R to an effector molecule (in this case, CD63) that is internalized and targeted for degradation in lysosomes. In other words, this example was designed to examine whether the normal internalization and degradation of CD63 could be used to enhance the reconfiguration of the internalization and degradation pathway of IL-4R in cells.

[0069] First, a multispecific antigen-binding molecule capable of binding to both IL-4R and CD63 was constructed. Specifically, a streptavidin-conjugated anti-IL-4R antibody and a biotinylated anti-CD63 antibody were mixed in a 1:1 ratio to generate an anti-IL-4R:anti-CD63 conjugate (i.e., a multispecific antigen-binding molecule that specifically binds to both IL-4R and CD63). The anti-IL-4R antibody used in this example is a fully human mAb raised against the IL-4R extracellular domain. (The anti-IL-4R antibody contained a heavy chain variable region having SEQ ID NO:3 and a light chain variable region having SEQ ID NO:4). The anti-CD63 antibody used in this example is a mouse anti-human CD63 mAb clone MEM-259 obtained from Biolegend (San Diego, CA), catalog number 312002.

[0070] Two control constructs were also generated: control-1 = streptavidin-conjugated anti-IL-4R antibody mixed with biotinylated control mouse IgG1 kappa antibody in a 1:1 ratio; and control-2 = streptavidin-conjugated anti-IL-4R antibody mixed with non-biotinylated anti-CD63 antibody in a 1:1 ratio. The anti-IL-4R antibody used in the experimental and control constructs for this example is an antibody that is known to specifically bind to IL-4R but only partially block IL-4-mediated signaling.

[0071] The experimental cell line used in this example is a HEK293 cell line ("HEK293 / STAT6-luc cell") that contains a STAT6-luciferase reporter construct and additional STAT6. The cells used in this experiment express both IL-4R and CD63 on their surface. When treated with IL-4 in the absence of any inhibitor, this cell line produces a dose-dependent detectable chemiluminescence signal, which reflects the degree of IL-4-mediated signal transduction.

[0072] In the first experiment, the experimental anti-IL-4R / anti-CD63 multispecific molecules or the control construct were added to HEK293 / STAT6-luc cells such that the final concentration of anti-IL-4R antibody in the medium was 12.5 nM. Increasing concentrations of IL-4 were added in the presence and absence of the experimental and control constructs, and the reporter signal was measured (Figure 3). As can be seen in Figure 3, the anti-IL-4R / anti-CD63 multispecific molecules ("antibody conjugates") inhibited IL-4-mediated signaling to a significantly greater extent than the control construct.

[0073] To confirm that the effects observed in Figure 3 were dependent on CD63, the same experiment as above was performed, except that CD63 expression was significantly reduced in the reporter cell line using siRNA against CD63. When CD63 expression was significantly reduced, the enhanced inhibitory activity of the anti-IL-4R / anti-CD63 multispecific molecule was no longer observed (Figure 4). This result suggests that the ability of the anti-IL-4R / anti-CD63 multispecific molecule to attenuate IL-4-mediated signaling is due to the simultaneous binding of the multispecific molecule to IL-4R and CD63, and the subsequent internalization and degradation of the entire antibody-IL-4R-CD63 complex.

[0074] Similar experiments were then performed in which anti-IL-4R / anti-CD63 multispecific molecules or control constructs were incubated with the HEK293 / STAT6-luc reporter cell line for various periods of time before the addition of IL-4. In a first set of such experiments, the molecules were incubated with the reporter cell line for 0 hours (i.e., added simultaneously with IL-4), 2 hours, or overnight before the addition of 50 pM IL-4. Luciferase activity was measured 6 hours after the addition of IL-4. The results are shown in the top panel of Figure 5 ("Non-transfected"). In a further set of experiments, a similar protocol was performed in which the experimental or control molecules were incubated with the reporter cell line for 15 minutes, 30 minutes, 1 hour, or 2 hours before the addition of 50 pM IL-4. The results are shown in Figure 6.

[0075] The results summarized in Figures 5 and 6 show that anti-IL-4R / anti-CD63 multispecific molecules can inhibit IL-4-mediated signaling and that this inhibitory effect is enhanced with longer incubation times. For the first set of experiments, the dependence of the inhibitory effect of anti-IL-4R / anti-CD63 multispecific molecules on CD63 expression was confirmed using CD63 siRNA (Figure 5, lower panel ["CD63 siRNA"]).

[0076] In summary, this example provides further proof of concept for the inhibition of target molecule activity through the use of a multispecific antigen binding molecule that can simultaneously bind both a target molecule (in this case IL-4R) and an internalizing effector protein (in this case CD63), thereby causing the internalization and re-routing of the target molecule within the cell. In other words, the simultaneous binding of the exemplary multispecific antigen binding molecule to IL-4R and CD63 attenuated the activity of IL-4R to a substantially greater extent (i.e., >10%) than when only the control construct binds to IL-4R.

[0077] Example 3. Anti-IL-4R x anti-CD63 bispecific antibody attenuates IL-4R activity in a CD63-dependent manner The experiments in Example 2 herein show that anti-IL-4R / anti-CD63 multispecific molecules inhibit IL-4-mediated signaling in a CD63-dependent manner. In those experiments, the multispecific antigen-binding molecule consisted of two different monoclonal antibodies (anti-IL-4R and anti-CD63) linked via biotin-streptavidin linkages. To confirm that the results observed for the proof-of-concept multispecific antigen-binding molecule can be generalized to other multispecific antigen-binding molecule formats, a true bispecific antibody was constructed.

[0078] Using standard bispecific antibody technology, a bispecific antibody was constructed consisting of a first arm specific for IL-4R and a second arm specific for CD63. The IL-4R-specific arm contained an anti-IL-4R heavy chain paired with a CD63-specific light chain. The CD63-specific light chain was paired with the IL-4R-specific heavy chain solely for the purpose of ease of construction; nevertheless, pairing the anti-IL-4R heavy chain with the anti-CD63 light chain retained full specificity for IL-4R and showed no binding to CD63. The CD63-specific arm contained an anti-CD63 heavy chain paired with an anti-CD63 light chain (the same light chain used in the IL-4R arm). The anti-IL-4R heavy chain (including SEQ ID NO:3) was derived from the complete anti-IL-4R antibody used in Example 2. However, the anti-CD63 heavy and light chains were derived from an anti-CD63 antibody called H5C6 obtained from the Developmental Studies Hybridoma Bank (University of Iowa Department of Biology, Iowa City, IA). Similar to the complete anti-IL-4R antibody used in Example 2, the anti-IL-4R component of the bispecific antibody used in this example exhibited only modest IL-4R blocking activity alone.

[0079] To evaluate the blocking activity of anti-IL-4R x anti-CD63 bispecific antibodies, an IL-4 luciferase assay was performed. Briefly, serial dilutions of anti-IL-4R x anti-CD63 bispecific antibodies or control molecules were added to HEK293 / STAT6-luc reporter cells (see Example 2). Under normal conditions, these cells produce a detectable luciferase signal when treated with IL-4. For this experiment, 10 pM IL-4 was added to the cells and luciferase activity was quantified for each dilution of antibody used. The controls used in this assay were (a) a pseudo-bispecific antibody that binds to IL-4R with one arm and has a non-functional anti-CD63 arm (i.e., containing one anti-IL-4R heavy chain and one anti-CD63 heavy chain, both of which are paired with an anti-IL-4R light chain); (b) an anti-IL-4R monospecific antibody; and (c) buffer (PBS) only (no antibody). The results are shown in Figure 7. As shown in Figure 7, for the control samples used, luciferase activity remained relatively high even at the highest antibody concentration, whereas in the case of the bispecific antibody, luciferase activity decreased significantly with increasing antibody concentration. These results confirm that simultaneous binding of IL-4R and CD63 by the bispecific antibody causes a substantial inhibition of IL-4R activity.

[0080] Example 4. Internalization of SOST using a multispecific antigen-binding molecule that simultaneously binds SOST and CD63 In this example, we evaluated whether a multispecific antigen-binding molecule promotes the internalization of the soluble target molecule SOST (skerostin). For these experiments, the target molecule was a fusion protein consisting of human SOST protein tagged with a pHrodo™ moiety (Life Technologies, Carlsbad, CA) and a myc tag. The pHrodo™ moiety is a pH-sensitive dye that is virtually non-fluorescent at neutral pH but brightly fluoresces in acidic environments such as endosomes. Therefore, the fluorescent signal can be used as an indicator of intracellular internalization of the SOST fusion protein. The multispecific antigen-binding molecule for these experiments was a bispecific antibody with binding specificity for both CD63 (an internalizing effector protein) and the SOST fusion protein (a soluble target molecule), as described in more detail below.

[0081] The experiments were performed as follows. Briefly, HEK293 cells were plated at 10,000 cells / well in poly-D-lysine coated 96-well plates (Greiner Bio-One, Monroe, NC). After allowing the cells to settle overnight, the medium was replaced with medium containing antibodies (5 μg / mL, as described below), pHrodo™-myc-tagged SOST (5 μg / mL), heparin (10 μg / mL), and Hoechst 33342. The cells were then incubated for 3 hours on ice or at 37° C. for 3 hours. All cells were washed twice in PBS prior to imaging and the number of fluorescent spots per cell as well as the corresponding fluorescence intensity were counted to establish the extent of pHrodo-myc-tagged SOST cellular internalization in the presence of the various antibody constructs.

[0082] The antibodies used in this example were as follows: (1) anti-CD63 monospecific antibody (clone H5C6, Developmental Studies Hybridoma Bank, University of Iowa Department of Biology, Iowa City, IA); (2) anti-myc antibody (clone 9E10, Schiweck et al., 1997, FEBS Lett. 414(1):33-38); (3) anti-SOST antibody (an antibody having heavy and light chain variable regions of the antibody referred to as "Ab-B" in U.S. Pat. No. 7,592,429); (4) anti-CD63 x anti-myc bispecific antibody (i.e., a multispecific antigen binding molecule comprising an anti-CD63 arm derived from antibody H5C6 and an anti-myc arm derived from 9E10); (5) anti-CD63 x anti-SOST bispecific antibody #1 (i.e., a multispecific antigen binding molecule comprising an anti-CD63 arm derived from antibody H5C6 and an anti-SOST arm derived from "Ab-B"); and (6) anti-CD63 x anti-SOST bispecific antibody #2 (i.e., a multispecific antigen binding molecule comprising an anti-CD63 arm derived from antibody H5C6 and an anti-SOST arm derived from the antibody referred to as "Ab-20" in U.S. Pat. No. 7,592,429). The bispecific antibodies used in these experiments were assembled using the so-called "knobs-into-holes" methodology (see, e.g., Ridgway et al., 1996, Protein Eng. 9(7):617-621).

[0083] The results of the internalization experiments are shown in Figure 8, which shows the number of spots (labeled vesicles) per cell under the various treatment conditions tested. Taken together, the results of these experiments demonstrate that bispecific constructs that simultaneously bind CD63 and SOST (directly or via myc tags) caused the greatest amount of SOST internalization, as reflected by the fluorescence intensity and number of fluorescent spots per cell over time at 37°C. Thus, the multispecific antigen binding molecules used in this example can effectively direct the internalization of soluble target molecules.

[0084] Example 5. Changes in bone mineral density in mice treated with a multispecific antigen binding molecule that binds CD63 and SOST The anti-CD63 x anti-SOST multispecific antigen binding molecules described in Example 4 were then examined for their ability to increase bone mineral density in mice. Five groups of mice (approximately 6 mice per group) are used in these experiments. The treatment groups are as follows: (I) untreated negative control mice; (II) mice treated with a blocking anti-SOST monospecific antibody known to increase bone mineral density alone (positive control); (III) mice treated with a bispecific antibody that specifically binds to CD63 and SOST but does not inhibit SOST activity alone or inhibits SOST activity only slightly alone; (IV) mice treated with an anti-CD63 parent antibody (i.e., a monospecific antibody that contains the same anti-CD63 antigen binding domain as the bispecific antibody); and (V) mice treated with an anti-SOST parent antibody (i.e., a monospecific antibody that contains the same anti-SOST antigen binding domain as the bispecific antibody). The amount of antibody administered to each group of mice is approximately 10 to 25 mg / kg.

[0085] Group III mice (treated with anti-SOST x anti-CD63 bispecific antibody) are expected to show an increase in bone mineral density that is at least equivalent to that observed in Group II mice (treated with a known blocking anti-SOST antibody), even though the anti-SOST component of the bispecific antibody alone does not inhibit SOST activity (as confirmed by Group V mice, which are expected to show no increase in bone mineral density). The expected increase in bone mineral density in Group III mice is believed to be driven by CD63-mediated internalization of SOST as observed in the cell experiments of Example 4 above.

[0086] Example 6. Cellular internalization of lipopolysaccharide (LPS) mediated by a multispecific antigen-binding molecule that simultaneously binds LPS and CD63 This example describes the use of the multispecific antigen-binding molecules of the present invention to direct the internalization of a non-protein target molecule, namely lipopolysaccharide (LPS). LPS is a component of the outer membrane of Gram-negative bacteria and is known to contribute to septic shock. Anti-LPS antibodies have been investigated as a possible treatment for sepsis. The experiments in this example were designed to evaluate whether the multispecific antigen-binding molecules can promote the internalization of LPS.

[0087] The multispecific antigen-binding molecule used in this example was a bispecific antibody with one arm against LPS (target) and another arm against CD63 (internalizing effector protein). The anti-LPS arm was derived from an antibody known as WN1 222-5 (DiPadova et al., 1993, Infection and Immunity 61(9):3863-3872; Muller-Loennies et al., 2003, J. Biol. Chem. 278(28):25618-25627; Gomery et al., 2012, Proc. Natl. Acad. Sci USA 109(51):20877-20882; US 5,858,728). The anti-CD63 arm was derived from the H5C6 antibody (see Example 4). Anti-LPS x anti-CD63 bispecific antibodies (i.e., multispecific antigen-binding molecules) were assembled using the so-called "knobs-into-holes" methodology (see, e.g., Ridgway et al., 1996, Protein Eng. 9(7):617-621).

[0088] Two LPS species were used in these experiments: Escherichia coli LPS and Salmonella minnesota LPS. Both forms were obtained as fluorescently labeled molecules (ALEXA-FLUOR®-488 labeled LPS, Life Technologies, Carlsbad, CA).

[0089] The experiment was performed as follows: HEK293 cells were plated in 96-well PDL-coated imaging plates. After resting overnight, the medium was replaced with fresh medium. Fluorescently labeled LPS (from E. coli or S. minnesota) was added to the normal medium. Anti-LPS x anti-CD63 bispecific antibody or control half antibody paired with dummy Fc was then added to the samples. After various incubation times at 37°C (1 hr and 3 hr) or on ice (3 hr), cells from LPS-treated samples were treated as follows: wash - quench with anti-ALEXA-FLUOR®-488 antibody - wash & fix. Anti-ALEXA-FLUOR®-488 antibody quenches the fluorescence from non-internalized (i.e. surface-bound) fluorophores. Thus, any fluorescence observed in the quenching antibody-treated samples is due to internalized LPS. Fluorescence levels were measured for each sample at various time points.

[0090] Figure 9 presents the results of these experiments in terms of the number of labeled vesicles per cell. As shown in Figure 9, only cells treated with anti-CD63 x anti-LPS bispecific antibody showed a significant number of labeled vesicles that increased with time. Cells treated with labeled LPS and control antibody did not show appreciable numbers of fluorescent vesicles, indicating that LPS was not internalized under those treatment conditions.

[0091] Thus, this example demonstrates that anti-LPS x anti-CD63 bispecific antibodies cause LPS internalization into cells in a manner that requires simultaneous binding of LPS and CD63. Thus, these results support the use of multispecific antigen-binding molecules of the present invention to promote cellular internalization of target molecules such as LPS to treat diseases and disorders such as sepsis.

[0092] The present invention is not limited in scope by the specific embodiments described herein. Indeed, various modifications of the present invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

Claims

1. (i) a first antigen-binding domain (D1) that specifically binds to a target molecule (T) that is a tumor-associated antigen; and (ii) a second antigen-binding domain (D2) that binds to a membrane-associated molecule (E) selected from the group consisting of transferrin receptor, APLP2, and ASGR1; A multispecific antigen-binding molecule comprising: The binding affinity of D2 to E is weaker than the binding affinity of D1 to T, the multispecific antigen-binding molecule selectively targets tumor cells expressing T, and simultaneous binding of the multispecific antigen-binding molecule to T and E results in forced internalization and degradation of T within the tumor cells through its physical linkage to E. Multispecific antigen binding molecules.

2. The multispecific antigen-binding molecule of claim 1, wherein the multispecific antigen-binding molecule is in a form for administration to a patient in which it is desirable and / or beneficial to inactivate, attenuate or otherwise reduce the extracellular concentration of T.

3. (a) D1 and D2 comprise a heavy chain variable region (HCVR) and a light chain variable region (LCVR), respectively; (b) the multispecific antigen-binding molecule comprises or consists of a recombinant human antibody or an antigen-binding fragment thereof; (c) the multispecific antigen-binding molecule is a bispecific antibody; (d) T is internalized as a complex consisting of a multispecific antigen-binding molecule co-bound to T and E; or (e) the multispecific antigen-binding molecule is conjugated to a drug, a toxin, or a radioisotope; A multispecific antigen-binding molecule according to claim 1 or 2.

4. The multispecific antigen-binding molecule of any one of claims 1 to 3, wherein the multispecific antigen-binding molecule does not block the interaction between T and a binding partner of the T.

5. The multispecific antigen-binding molecule of any one of claims 1 to 4, wherein simultaneous binding of the multispecific antigen-binding molecule to T and E weakens the activity of T more than when only D1 binds to T.

6. The multispecific antigen-binding molecule of any one of claims 1 to 5, wherein D1 and / or D2 exhibit pH-dependent binding to the antigen.

7. The multispecific antigen-binding molecule of claim 6, wherein D1 binds to T with lower affinity at acidic pH compared to neutral pH; and / or D2 binds to E with lower affinity at acidic pH compared to neutral pH.

8. The multispecific antigen-binding molecule of any one of claims 1 to 7, wherein the activity of T in the presence of the multispecific antigen-binding molecule is at least 10% lower than the activity level of T measured in the presence of a control construct comprising only D1.

9. The multispecific antigen-binding molecule of any one of claims 1 to 8, wherein the binding affinity of D2 to E is at least 10% weaker than the binding affinity of D1 to T.

10. The multispecific antigen-binding molecule of any one of claims 1 to 9, wherein D2 interacts with E with a KD of greater than about 10 nM to about 1 μM when measured in a surface plasmon resonance assay at about 25°C.

11. A multispecific antigen-binding molecule according to any one of claims 1 to 10 for use in the treatment of a patient in need thereof.

12. The multispecific antigen-binding molecule of any one of claims 1 to 11, wherein the multispecific antigen-binding molecule comprises one multifunctional polypeptide or two or more polypeptides associated with each other by covalent or non-covalent bonds.

13. (a) D1 is formed by the D1 immunoglobulin light chain variable region and the D1 immunoglobulin heavy chain variable region; and (b) D2 is formed by a D2 immunoglobulin light chain variable region and a D2 immunoglobulin heavy chain variable region; A multispecific antigen-binding molecule according to any one of claims 1 to 12.

14. The multispecific antigen-binding molecule of any one of claims 1 to 12, wherein D2 comprises (i) an antigen-binding portion of an antibody that binds to E, or (ii) a ligand or portion of a ligand that binds to E.

15. The multispecific antigen-binding molecule of any one of claims 1 to 12, wherein D1 comprises (i) an antigen-binding domain of an antigen-binding molecule that binds to T but does not substantially inactivate T alone, or (ii) a ligand that binds to T.

16. The multispecific antigen-binding molecule of any one of claims 1 to 15, wherein the binding affinity of D2 to E is at least 90% weaker than the binding affinity of D1 to T.

17. 20. Use of (a) a multispecific antigen-binding molecule of any one of claims 1 to 16, and (b) a second antigen-binding protein that specifically binds to T at an epitope that does not overlap with the epitope bound by D1, in the manufacture of a medicament for treating a tumor in a subject.

18. 18. The use of claim 17, wherein the second antigen binding protein is conjugated to a drug, a toxin or a radioisotope.

19. 20. Use of (a) a multispecific antigen-binding molecule according to any one of claims 1 to 16, and (b) a second antigen-binding protein that specifically binds to T at an epitope that does not overlap with the epitope bound by D1, in the manufacture of a medicament for targeting a tumor in a subject.

20. 20. The use of claim 19, wherein the second antigen binding protein is conjugated to a drug, a toxin or a radioisotope.

21. The use according to any one of claims 17 to 20, wherein D2 binds to E with a KD of greater than about 10 nM when measured in a surface plasmon resonance assay at about 25°C.

22. An in vitro method for inactivating a target molecule or attenuating the activity of a target molecule, comprising contacting a target molecule comprising T and a cell expressing E on its surface with a multispecific antigen-binding molecule described in any one of claims 1 to 16.

Citation Information

Patent Citations

  • Induced internalization of surface receptors

    WO2009094561A1